The Company granted certain stock options under the 2019 Plan, and currently grants certain stock options under the 2020 Plan, which are considered common stock equivalents. Unvested restricted stock units granted under the 2020 Plan are also considered common stock equivalents. The Company uses the treasury stock method to calculate weighted-average diluted shares outstanding. For the periods ending June 30, 2025 and June 30, 2024, the common stock equivalents were excluded from the calculation of net loss per share due to their anti-dilutive effect.

The following table summarizes the impact of the treasury stock method:


Net loss per share	Three Months Ended June 30						Six Months Ended June 30,
(in thousands, except per share amounts)	2025			2024			2025			2024
Numerator
Net loss attributable to common stockholders		(78,729	)		(7,128	)	$	(113,341	)	$	(45,344	)
Denominator
Weighted-average shares used in compute net loss per share, basic		43,564,573			39,699,053			43,403,850			37,771,084
Effect of dilutive securities (a)		—			—			—			—
Weighted-average shares used to compute net loss per share, diluted		43,564,573			39,699,053			43,403,850			37,771,084
Net loss per share:
Basic	$	(1.81	)	$	(0.18	)	$	(2.61	)	$	(1.20	)
Diluted	$	(1.81	)	$	(0.18	)	$	(2.61	)	$	(1.20	)

(a) The common stock equivalents, which equaled 846,919 and 1,439,199 stock awards outstanding for the three and six months ended June 30, 2025, respectively, and 1,884,542 and 2,028,359 stock awards outstanding for the three and six months ended June 30, 2024, were excluded for the period then ended, respectively, due to their anti-dilutive effect.

In accordance with ASC 260, Earnings Per Share, the shares of common stock underlying the pre-funded warrants are considered shares issuable for little or no cash consideration, and are therefore included in the calculation of basic net loss per share in the above table.